BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, July 4, 2026
See today's BioWorld
Home » BCL6 degrader works via combine and conquer strategy
To read the full story, subscribe or sign in.

BCL6 degrader works via combine and conquer strategy

Nov. 24, 2020
By W. Todd Penberthy
The BCL6 degrader BI-3802 works by inducing polymerization of its target protein, which in turn triggers the addition of ubiquitin tags on the polymerized structure and degradation by the proteasome, scientists reported in the Nov. 18, 2020, issue of Nature.
Science Cancer

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 2, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 30, 2026
  • Black wavy lines forming an abstract sound wave.png

    Deep brain stimulation from the shallows: tomorrow’s BCI technology?

    BioWorld
    Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
  • Brain made of chip and circuits

    Ascending BCI systems deepen national security, ethical concerns

    BioWorld
    Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...
  • Handshake, businessmen holding dollar sign, lightbulb

    Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal

    BioWorld
    A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing